Part B of the Ryan White HIV/AIDS Treatment Extension Act of 2009 (Public Law 111-87) provides grants to States and U.S. Territories. The AIDS Drug Assistance Program (ADAP) is a State/Territory-administered program authorized under Part B that provides FDA-approved medications to low-income people living with HIV who have limited or no health coverage from private insurance, Medicaid, or Medicare. ADAP funds may also be used to purchase health insurance for eligible clients and for services that enhance access to, adherence to, and monitoring of drug treatments.
Part B grant recipients are the chief elected official of a State/Territory who designates the state departments of health or other state governmental entities to implement and manage the RWHAP Part B grant. Part B grants are awarded to all 50 states, the District of Columbia, Puerto Rico, Guam, the U.S. Virgin Islands, and the six U.S. Pacific Territories or Associated Jurisdictions.
Client eligibility is determined by the state and territory and includes financial and medical eligibility criteria. Financial eligibility is usually determined as a percentage of the Federal Poverty Level. Medical eligibility is a diagnosis of HIV.
The RWHAP legislation requires that each ADAP must cover at least one drug from each class of HIV antiretroviral medications on their ADAP formulary. RWHAP funds may only be used to purchase FDA-approved medications. Within these requirements, each ADAP decides which medications to include on its formulary and how those medications will be distributed.
HRSA requires that ADAP eligibility criteria must be consistently applied across the State/Territory, and that all formulary medications and ADAP-funded services must be equally and consistently available to all eligible enrolled people throughout the State/Territory.
More information on ADAP requirements can be found in the ADAP Manual (PDF 559KB).